CGH
PTCT icon

Crossmark Global Holdings’s PTC Therapeutics PTCT Stock Holding History

Crossmark Global Holdings’s Portfolio PTCT Stock Details PTCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$217K Buy
+2,658
New +$192K ﹤0.01% 1200

Other funds holding PTCT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Toronto Dominion Bank
Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $86.4B AUM 59.51% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return

Crossmark Global Holdings's PTCT Position: Q2 2026 in Review

Crossmark Global Holdings opened a new position in PTC Therapeutics (PTCT) in Q2 2026: 2,658 shares worth $217K. The stake represents ﹤0.01% of the portfolio and ranks #1200 among its holdings.

382 funds tracked by Wall St. Rank hold PTCT as of Q2 2026.

  • Crossmark Global Holdings held 2,658 shares of PTC Therapeutics worth $217K as of Q2 2026.
  • PTC Therapeutics was a new Crossmark Global Holdings position in Q2 2026.
  • PTC Therapeutics made up ﹤0.01% of Crossmark Global Holdings's portfolio in Q2 2026, its #1200 holding.
  • 382 funds tracked by Wall St. Rank held PTC Therapeutics as of Q2 2026.

Based on Crossmark Global Holdings's 13F filing for Q2 2026, filed 16 Jul 2026.